Drug Profile
Research programme: thrombosis therapeutics - AstraZeneca
Alternative Names: AZD 1283Latest Information Update: 17 Dec 2007
Price :
$50
*
At a glance
- Originator AstraZeneca
- Class
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Thrombosis
Most Recent Events
- 20 Feb 2007 Preclinical trials in Thrombosis in United Kingdom (unspecified route)